Thermo Fisher Scientific will divest its anatomical pathology business for $1.1 billion to PHC Holdings. The sale leaves Thermo Fisher in a competitive M&A position among bioprocessing peers, says an analyst. The business unit, part of Thermo Fisher’s Specialty Diagnostics Segment, includes microscope slides, instruments and consumables and will be taken over by Japan’s PHC Holdings Corporation – formerly Panasonic Healthcare Holdings – if the deal goes through in the second quarter of 2019. The unit generates about $85 million…